[go: up one dir, main page]

AR043395A1 - COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS - Google Patents

COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS

Info

Publication number
AR043395A1
AR043395A1 ARP040100592A ARP040100592A AR043395A1 AR 043395 A1 AR043395 A1 AR 043395A1 AR P040100592 A ARP040100592 A AR P040100592A AR P040100592 A ARP040100592 A AR P040100592A AR 043395 A1 AR043395 A1 AR 043395A1
Authority
AR
Argentina
Prior art keywords
lercanidipine
angiotensin
hypertension
blocker
receptors
Prior art date
Application number
ARP040100592A
Other languages
Spanish (es)
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of AR043395A1 publication Critical patent/AR043395A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La lercanidipina se utiliza en la preparación de un medicamento para el tratamiento de la hipertensión en combinación con la administración previa, concurrente o posterior de un bloqueante de los receptores de angiotensina II (ARB) seleccionado de olmesartán, irbesartán, valsartán, telmisartán y losartán. Se reivindican las composiciones que obtienen tanto lercanidipina como el ARB.Lercanidipine is used in the preparation of a medication for the treatment of hypertension in combination with the previous, concurrent or subsequent administration of an angiotensin II receptor blocker (ARB) selected from olmesartan, irbesartan, valsartan, telmisartan and losartan. Compositions that obtain both lercanidipine and ARB are claimed.

ARP040100592A 2003-02-28 2004-02-25 COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS AR043395A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45086403P 2003-02-28 2003-02-28
US45078203P 2003-02-28 2003-02-28

Publications (1)

Publication Number Publication Date
AR043395A1 true AR043395A1 (en) 2005-07-27

Family

ID=32930575

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100592A AR043395A1 (en) 2003-02-28 2004-02-25 COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS

Country Status (4)

Country Link
AR (1) AR043395A1 (en)
CL (1) CL2004000379A1 (en)
TW (1) TW200501953A (en)
WO (1) WO2004075892A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050922A1 (en) * 2004-11-11 2006-05-18 Lek Pharmaceuticals D.D. Process for the synthesis of tetrazoles
CN1298389C (en) * 2005-01-18 2007-02-07 广东省人民医院 Compound preparation of calcium antagonist and timishatan for reducing blood pressure and its use
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
KR101247583B1 (en) * 2006-12-08 2013-03-26 한미사이언스 주식회사 Pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof
DE102008059206A1 (en) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic
CN102600146B (en) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
MX2015002170A (en) * 2015-02-18 2016-08-17 Invekra S A P I De C V Novel pharmaceutical compositions useful for treating hypertension.
MX2015002169A (en) * 2015-02-18 2016-08-17 Invekra S A P I De C V Pharmaceutical compositions for treating hypertension, based on a novel drug combination.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
ITMI20011726A1 (en) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma POLYMORPHIC FORMS OF LERCANIDIPINE HYDROCHLORIDE

Also Published As

Publication number Publication date
CL2004000379A1 (en) 2005-01-21
WO2004075892A3 (en) 2004-09-30
TW200501953A (en) 2005-01-16
WO2004075892A2 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
CY1125077T1 (en) TREATMENT OF VITAMIN D DEFICIENCY AND DEFICIENCY WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3
CY1110989T1 (en) USE OF 3- (4-AMINO-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidino-2,6-dione for the treatment of human lymph nodes
AR051618A1 (en) COMPRESSED BICYCLE AND METHOD
CL2008001946A1 (en) Imidazole-derived compounds, ccr2, ccr3, ccr5 receptor antagonists; preparation procedure; and use in the treatment of peripheral vascular diseases.
CL2007001174A1 (en) Compounds derived from 4h- [1,2,4] triazol-3-yl, which exhibit activity in metabotropic glutamate receptors; intermediary compounds; pharmaceutical composition comprising the compounds; pharmaceutical combination that includes the compounds; and use of the compounds in the preparation of medications
CL2004000860A1 (en) BICYCLE COMPOUND OF PIRAZOL OR IMIDAZOL OF DEFINED FORMULA, AS BINDING WITH THE CANNABINOID RECEIVER THAT ACTS AS AN ANTAGONIST OF THE CB1 RECEIVER; PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMPOUND AND USE OF THE COMPOUND IN THE PREPARATION OF A MEDICAM
CL2008002521A1 (en) Substituted pyrazole derivative compounds, androgen receptor antagonist; pharmaceutical composition comprising said compounds; and use of the compound for the treatment of cancer.
ECSP088692A (en) COMPOUNDS BASED ON IMIDAZOL, COMPOSITIONS THAT INCLUDE THE SAME AND METHODS OF THEIR USE
ECSP055840A (en) DERIVATIVES OF 4-TETRAZOLIL-4 PHENYLPIPERIDINE FOR THE TREATMENT OF PAIN
NO20060900L (en) Nitrooside derivatives of Losartan, Valsartan, Candesartan, Telmisartan, Eprosartan and Olmesartan as angiotensin II receptor blockers for the treatment of cardiovascular disease
CL2011003266A1 (en) Compounds derived from imidazolidin-2-one, with inhibitory activity of 17alpha-hydroxylase / lyase-c17,20; pharmaceutical composition comprising them; and use in the treatment of inflammation or cancer, among others.
BRPI0507887A (en) multilayer tablet
CL2010000188A1 (en) A method for treating an infection in a subject comprising the administration of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline or a salt thereof; pharmaceutical composition comprising said compound; and its use.
CL2008003595A1 (en) Nitrogen heterocyclic compounds, tachykinin receptor antagonists; pharmaceutical agent comprising the compound; and use in the prophylaxis or treatment of a lower urinary tract disease, a gastrointestinal disease, or a disease of the central nervous system.
PE20020082A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1)
AR067347A1 (en) ANTIHELMINTIC COMBINATION
AR043395A1 (en) COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS
ECSP066882A (en) IMIDAZOL COMPOUNDS
NO20090119L (en) Composition comprising controlled release nanoparticulated meloxicam and hydrocodone
CL2008001238A1 (en) Isolated anti-receptor antagonist antibody grig / pro362 / jam4 / stigma murine with deposit number atcc pat-8298; pharmaceutical composition; medical use to inhibit the complement-dependent cellulst entry mediated by crig of an intracellular pathogen (pi), or to prevent or treat an infection disease mediated by a pi
CL2008003811A1 (en) 4-aminopyrimidine-2,6-disubstituted derivative compounds, histamine h4 receptor antagonists; Preparation process; pharmaceutical composition comprising said compound; and use of the compound for the treatment of an allergic, immunological or inflammatory disease, or pain.
MX2010001574A (en) Cannabinoid receptor ligands.
CL2004000545A1 (en) USE OF AN ANTAGONIST OF ALDOSTERONE RECEPTORS AND AN ENDOTHELINE RECEIVER ANTAGONIST FOR THE TREATMENT OR PROFILAXIS OF A PATHOLOGICAL CONDITION RELATED TO HYPERTENSION, RENAL DYSFUNCTION, INSULINOPATHY AND CARDIOVASCUL DISEASES
CY1114933T1 (en) STRONG POWERFUL MEDICINAL COMPOSITIONS CONTAINING IRESARTARTAN AND AMLODIPIN, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
CL2008003266A1 (en) Compounds derived from cycloguanidine substituted pyrimidinedione and triazinedione, useful as a prokineticin receptor antagonist; pharmaceutical composition comprising said compounds; and use in the treatment of gastrointestinal diseases.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure